Clinical and Research Safety Data Personal Peptide Safety: CJC-1295 without DAC has been studied in clinical trials and shows good tolerability with minimal adverse effects at research doses, no major effects on cortisol or prolactin, good safety profile across dose ranges, and no serious adverse events in research studies
These include, for example, searching for new bacterial targets (such as bacterial virulence factors), using microbial symbionts-derived antibacterial agents, and drug repositioning
Human studies on moringa are small, short-term, and methodologically inconsistent, making it impossible to draw firm clinical conclusions about weight reduction
The practical consequence is a delayed, accumulating effect the opposite of a stimulant's immediate hit
doi:10.1515/cclm-2012-0465 Spence JD